Albert Einstein Cancer Center awarded NIH grant

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE ALBERT EINSTEIN CANCER CENTER and the Montefiore Einstein Center for Cancer Care received a Ruth L. Kirschstein NRSA Institutional Research Training Grant from NIH, which will provide $1.18 million in funding over five years.

This new competitive program is designed so that surgical residents in training spend two additional years in hands-on training as research fellows focused on the study of malignant tumors, the role of the immune system in tumor growth inhibition and the identification of emerging novel targets.

The 15 faculty members guiding this training, both as educators and mentors, represent six clinical and four basic science departments. Participating research fellows are expected to submit at least two abstracts to national meetings and at least one original manuscript for peer review by the completion of their training.

Table of Contents

YOU MAY BE INTERESTED IN

The tremendous promise—and potential peril—of the prostate-specific antigen (PSA) screening test have confounded guideline developers for decades. When introduced, PSA was one of the first and the only credible blood biomarkers for cancer screening. That a simple blood test should be used to screen for the most common cancer in men, one that was lethal for 3% of men and 5% of Black men, seemed like a slam dunk. 
With artificial intelligence becoming an increasingly ubiquitous part of the fabric of modern life, Cancer Grand Challenges has committed $10 million to a project aimed at developing AI “co-scientists”—AI agents that could help cancer researchers analyze data, generate hypotheses, and suggest new experiments.
For decades, cancer treatment has largely followed a familiar model: Identify the disease, determine its stage, and select the therapy most likely to benefit patients with similar characteristics. Even as targeted therapies and immunotherapies have transformed oncology, we have generally developed drugs for populations rather than individuals.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login